BriaCell (BCTX) Therapeutics announces that the National Cancer Institute, NCI, the United States federal government’s principal agency for cancer research and training, has awarded the Company a research grant of $2,054,651 to advance Bria-PROS+, BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancer. The non-dilutive grant, titled “Phase 1/2a clinical trial to investigate Bria-PROS+ in patients with metastatic prostate cancer”, will be used to complete manufacturing of Bria-PROS+ and to fund the upcoming Phase 1/2a study in patients with advanced prostate cancer.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BCTX:
- BriaCell Therapeutics trading halted, news pending
- BriaCell Announces Share Consolidation to Meet Nasdaq Requirements
- BriaCell to effect 1-for-10 share consolidation on August 25
- BriaCell Joins MSK’s 2025 Therapeutics Accelerator Program
- BriaCell selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+